Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Controlling Myopia: Insights from a Nation-Wide Clinical Practice Survey.

Journal of clinical medicine·2026
Same author

Ethnic Differences in the Presentation Patterns of Type 3 Macular Neovascularization.

Retina (Philadelphia, Pa.)·2026
Same author

Levofloxacin/ketorolac combination versus levofloxacin alone for topically treating moderate-severe acute bacterial conjunctivitis: a randomized controlled trial.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2026
Same author

Two-years efficacy and safety of bleb forming devices in uncontrolled glaucoma.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2026
Same author

Isolated fourth cranial nerve palsy in a patient treated with pembrolizumab: a case report.

Strabismus·2026
Same author

Evaluation of Factors Influencing Quality of Life in Keratoconus Patients Using the Keratoconus Outcomes Research Questionnaire (KORQ).

Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists)·2026

Related Experiment Videos

Supraciliary shunt in refractory glaucoma.

Michele Figus1, Stefano Lazzeri, Paolo Fogagnolo

  • 1Department of Neuroscience, Ophthalmology, University of Pisa, Via Paradisa, 2 - Edificio 30, Pisa 56100, Italy. figus@ocupisa.it

The British Journal of Ophthalmology
|August 30, 2011
PubMed
Summary
This summary is machine-generated.

Gold Micro Shunt (GMS) implantation successfully lowered intraocular pressure in refractory glaucoma patients. This glaucoma surgery achieved qualified success in 67.3% of eyes with minimal complications.

Related Experiment Videos

Area of Science:

  • Ophthalmology
  • Glaucoma Surgery
  • Medical Devices

Background:

  • Refractory glaucoma presents a significant challenge in intraocular pressure (IOP) management.
  • Previous surgical interventions often have limited efficacy or carry substantial risks.

Purpose of the Study:

  • To evaluate the efficacy and safety of Gold Micro Shunt (GMS) implantation for suprachoroidal drainage in patients with refractory glaucoma.
  • To assess the long-term outcomes of GMS in uncontrolled glaucoma cases.

Main Methods:

  • Prospective uncontrolled case series involving 55 eyes of 55 patients with refractory glaucoma.
  • GMS implantation into the supraciliary space.
  • Comprehensive follow-up over 24 months, including IOP measurements, slit-lamp examinations, and ultrasound biomicroscopy.

Main Results:

  • Mean baseline IOP was 30.8 ± 8.8 mm Hg, despite maximal medical therapy.
  • Qualified success (IOP reduction) was achieved in 67.3% of eyes after 2 years.
  • Mean IOP decreased to 13.7 ± 2.98 mm Hg, with a reduction in medication use from 2.5 to 1.4.
  • Mild hyphema was the most common side effect; membrane formation impacted efficacy in 12.2% of eyes.

Conclusions:

  • Gold Micro Shunt (GMS) is an effective option for suprachoroidal drainage in refractory glaucoma.
  • The procedure demonstrated qualified success in a significant majority of patients with a favorable safety profile.
  • Further research into mitigating membrane formation could enhance GMS efficacy.